GLPG Stock Analysis: Buy, Sell, or Hold?
GLPG - Galapagos NV
$27.73
-1.08 (-3.75%)
▼
5d:
-0.36%
30d:
-4.02%
90d:
-16.93%
BUY
MODERATE Confidence
Analysis Updated: May 7, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When GLPG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GLPG shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: GLPG shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GLPG is currently trading at $27.73, which is considered oversold relative to its 30-day fair value range of $28.14 to $29.03. From a valuation perspective, the stock is trading at a discount (Forward PE: -20.3) compared to its historical average (163.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GLPG is in a strong downtrend. The price is currently testing key support at $27.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GLPG is in a strong downtrend. The price is currently testing key support at $27.15. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$28.14 -
$29.03
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- NEUTRAL: Near Wall St target ($28.56)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$28.14 -
$29.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$27.15
Resistance Level
$28.97
Current Trend
Strong Downtrend
Technical data as of
May 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.32
Wall Street Target
$28.56
(+3.0%)
Revenue Growth (YoY)
1093.2%
Earnings Growth (YoY)
3036.0%
Profit Margin
28.8%
PE vs Historical
-20.3 vs 163.5
CHEAP
Share & Embed Analysis
Last updated: May 18, 2026 8:42 AM ET
Data refreshes hourly during market hours. Next update: 9:42 AM
Data refreshes hourly during market hours. Next update: 9:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLPG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
